Kura Oncology, Inc.
KURAHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. With a market capitalization of $1.01B, it sits in small-cap territory. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Market Cap
$1.01B
Beta
0.35
P/E (TTM)
—
P/E (Fwd)
-4.36
EPS (TTM)
$-3.38
EPS (Fwd)
$-2.60
ROE
-124.7%
ROA
-28.4%
Cash
$580.8M
Total Debt
$24.3M
Free CF
-$129.8M
52W Change
77.6%
Annual Financials
Cash vs Debt
Kura Oncology, Inc. holds $580.8M in cash against $24.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$129.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -124.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Kura Oncology, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kura Oncology, Inc.'s trajectory.